Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Cardiovascular Risk in Type 2 Diabetes (DOTAFLAME)
NCT05597202Phase 4Unknown
- Sponsor
- University of Amsterdam
- Start
- Jan 2023
- Primary completion
- Mar 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by University of Amsterdam. Status: unknown.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05597202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05597202.